• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Kaleido Biosciences Inc.

    4/25/22 4:41:02 PM ET
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLDO alert in real time by email
    S-8 POS 1 d344833ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on April 25, 2022

    Registration No. 333-238123

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO:

    FORM S-8 REGISTRATION STATEMENT NO. 333-238123

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    KALEIDO BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware
    (State or other jurisdiction
    of incorporation or organization)
      47-3048279
    (I.R.S. Employer
    Identification No.)

    65 Hayden Avenue

    Lexington, MA 02421

    (Address of principal executive offices, zip code)

     

     

    Kaleido Biosciences, Inc. 2019 Stock Option and Incentive Plan

    Kaleido Biosciences, Inc. 2019 Employee Stock Purchase Plan

    (Full title of the plans)

    Daniel L. Menichella

    Chief Executive Officer and President

    Kaleido Biosciences, Inc.

    65 Hayden Avenue

    Lexington, MA 02421

    (Name and address of agent for service)

    (617) 674-9000

    (Telephone number, including area code, of agent for service)

     

     

    with copies to:

    Kingsley L. Taft

    Laurie A. Burlingame

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.   ☒

     

     

     


    DEREGISTRATION OF SHARES

    This Post-Effective Amendment (this “Amendment”) relates to the following Registration Statement on Form S-8 (the “Registration Statement”) filed by Kaleido Biosciences Inc., a Delaware corporation (the “Company”) with the Securities and Exchange Commission (the “SEC”):

     

      •  

    Registration Statement No. 333-238123, filed on May 8, 2020, relating to the Kaleido Biosciences, Inc. 2019 Stock Option and Incentive Plan and the Kaleido Biosciences, Inc. 2019 Employee Stock Purchase Plan.

    The purpose of this Amendment is to deregister all remaining securities available for issuance under the Registration Statement. In accordance with the undertakings made by the Company in the Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, the Company hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Boston, Massachusetts, on April 25, 2022. No other person is required to sign this Amendment in reliance upon Rule 478 under the Securities Act of 1933.

     

    KALEIDO BIOSCIENCES, INC.
    By:  

    /s/ Theo Melas-Kyriazi

    Name:   Theo Melas-Kyriazi
    Title:   Director
    Get the next $KLDO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KLDO

    DatePrice TargetRatingAnalyst
    1/31/2022$11.00 → $3.00Buy
    Chardan Capital
    11/12/2021$15.00 → $11.00Buy
    Chardan Capital
    11/3/2021$25.00 → $22.00Market Outperform
    JMP Securities
    10/19/2021$3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $KLDO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Kaleido Biosciences with a new price target

      Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $3.00 from $11.00 previously

      1/31/22 9:22:16 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on Kaleido Biosciences with a new price target

      Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $11.00 from $15.00 previously

      11/12/21 7:22:49 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities reiterated coverage on Kaleido Biosciences with a new price target

      JMP Securities reiterated coverage of Kaleido Biosciences with a rating of Market Outperform and set a new price target of $22.00 from $25.00 previously

      11/3/21 7:54:29 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Radius Health Announces Leadership Appointments

      BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company's Chief Financial Officer. In addition, Kim Clarke has been promoted to the General Counsel position. Both will report to Kelly Martin, the Chief Executive Officer. Mark Conley is a Certified Public Accountant with over 30 years of experience in publicly listed companies. His experience includes all aspects of finance including business unit accounting, regulatory, corporate books and records, budget processes, internal & external audit a

      3/16/22 8:30:00 AM ET
      $KLDO
      $RDUS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Specialties
      Consumer Discretionary
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

      CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h

      2/15/22 10:05:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations

    $KLDO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 7, 2021 - Coronavirus (COVID-19) Update: September 7, 2021

      For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin

      9/7/21 4:11:11 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    Financials

    Live finance-specific insights

    See more
    • Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis

      KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal calprotectin, fecal lactoferrin, and FimH - observed at end of study Virtual R&D Presentation, highlighting the ulcerative colitis and chronic obstructive pulmonary disease programs, to be held today at 8:00 a.m. ET LEXINGTON, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore g

      10/5/21 7:00:00 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021

      Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented Call to feature leading experts in UC and Chronic Obstructive Pulmonary Disease (COPD) Company plans to advance both KB295 and KB109 to Phase 2 studies LEXINGTON, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it will host a virtual R&D Presentation on October 5, 2021, at 8 a.m. ET. The agenda will feature an update on the Company's corporate strategy, data from the non-IND stu

      9/29/21 7:30:00 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    SEC Filings

    See more
    • SEC Form 15-12B filed by Kaleido Biosciences Inc.

      15-12B - Kaleido Biosciences, Inc. (0001751299) (Filer)

      5/6/22 8:15:52 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Kaleido Biosciences Inc.

      EFFECT - Kaleido Biosciences, Inc. (0001751299) (Filer)

      5/2/22 12:15:14 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Kaleido Biosciences Inc.

      S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)

      4/25/22 4:42:53 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Kaleido Biosciences Inc. (Amendment)

      SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)

      5/10/22 10:13:04 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Kaleido Biosciences Inc. (Amendment)

      SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)

      2/9/22 9:22:49 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Kaleido Biosciences, Inc. (0001751299) (Subject)

      2/16/21 8:00:58 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Van Hylckama Vlieg Johan covered exercise/tax liability with 2,087 units of Restricted Stock Units, decreasing direct ownership by 31% to 4,620 units

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      3/2/22 4:09:49 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Korn Jerald covered exercise/tax liability with 2,046 units of Restricted Stock Units, decreasing direct ownership by 31% to 4,517 units

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      3/2/22 4:05:37 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Van Hylckama Vlieg Johan

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      1/18/22 5:18:21 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

      CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h

      2/15/22 10:05:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology

      CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.

      1/26/22 9:31:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations